CUPAB study

Clinical utility of plasma Amyloid beta biomarker : a multicenter validation study - CUPAB

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs032200043

Enrollment

200

Registered

2020-06-01

Start date

2020-07-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild cognitive impairment, Alzheimer's Disease (AD) , non- AD, Cognitively unimpaired individuals

Interventions

Injection of Flutemetamol, PET scan, brain MRI scan, blood sampling and Neuropsychological test.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cognitively unimpaired individuals; 1) Written informed consent is obtained. 2) General condition, visual acuity and hearing ability are sufficiently good to proceed examinations required for this study. Mild cognitive impairment, Alzheimer's Disease (AD) , non- AD; 1) Written informed consent is obtained.The subject's legally acceptable representative must provide the written informed consent form if the subject is unable to provide informed consent. 2) General condition, visual acuity and hearing ability are sufficiently good to proceed examinations required for this study. 3) Diagnosed with any of the following diseases at informed consent. Mild cognitive impairment Alzheimer's Disease (AD) non- AD

Exclusion criteria

Exclusion criteria: Cognitively unimpaired individuals; 1) GDS (Geriatric depression scale) > 6 2) Having difficulty to keep supine position due to deformity or dysfunction in the muscle-skeletal system, e.g. problems of the spine or hip joint. 3) Having contraindications for MRI scans. Mild cognitive impairment, AD , non- AD; 1) GDS > 11 2) Having difficulty to keep supine position due to deformity or dysfunction in the muscle-skeletal system, e.g. problems of the spine or hip joint. 3) Having contraindications for MRI scans.

Design outcomes

Primary

Measure	Time frame
Diagnostic accuracy of the plasma Amyloid beta biomarker to predict presence or absence of abnormal Amyloid beta deposition in the brain.	—

Secondary

Measure	Time frame
1) Sensitivity of the plasma Amyloid beta biomarker. 2) Specificity of the plasma Amyloid beta biomarker. 3) Probability of adverse events.	—

Contacts

Public ContactAkinori Nakamura

National Center for Geriatrics and Gerontology

nakamura@ncgg.go.jp+81-562-46-2311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026